Drug Profile


Alternative Names: NSC 130181; SR 259075; SR 4233; Tirazone; WIN 59075

Latest Information Update: 29 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SRI International; Stanford Cancer Institute
  • Developer SRI International; Teclison
  • Class Antineoplastics; Radiation-sensitising agents; Reducing agents; Small molecules; Triazines
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Colorectal cancer; Liver cancer
  • Discontinued Glioma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 Nov 2017 Teclison initiates enrolment in a phase II trial for liver cancer in USA (IV) (NCT03145558)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in liver cancer in Taiwan (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top